Leal Health (fka TrialJectory)

Name: Leal Health (fka TrialJectory)
Brand: Leal Health (fka TrialJectory)

The AI-powered patient-centric decision-support platform for patients, healthcare providers, pharma, and biotech.

Est 2017|Valuation $170M|Raised $53.7M|5 Ref Customers

LinkedIn 4K|Web traffic 1K|FTEs 18|HQ New York metropolitan area, Pennsylvania, US

Leal Health (fka TrialJectory) screenshot

Published Sep 29, 2026

01Common complaints

1. If independent, peer-reviewed evidence of enrollment acceleration or reduced screen-failure rates is required prior to procurement—public evidence is limited. 2. If the organization requires public-facing SOC 2 Type II or ISO 27001 documentation before engaging; such certifications were not identified in public sources. 3. If EHR-integrated cohort discovery of structured and unstructured clinical data is the primary need—EHR-integrated solutions may be a better fit. 4. If transparent, published enterprise pricing is required for procurement without a demo/negotiation process. 5. If the compliance team requires clear documentation on regulatory status for any decision-support claims and the vendor cannot provide clarifying documentation.

Disqualifiers / poor fit

Organizations that require publicly available, auditable security certifications prior to engagement
Programs that require EHR-native cohort discovery and prescreening at scale

Publicly visible limitations

Security documentation gap: Public-facing SOC/ISO attestations and enterprise controls were not found in the reviewed materials
Evidence gap: Vendor metrics are prominent in press materials, but independent evaluations and peer-reviewed studies are limited
Limited third-party review coverage: The product lacks a robust presence on mainstream B2B review platforms specific to the oncology offering

Roadmap / future features

Vendor materials reference enhancements such as generative AI additions and expanded support capabilities; detailed roadmap timelines are not publicly available.

02Why they buy

Unique selling points reflected in vendor materials (subject to independent validation)

A single workflow that includes trial matching and summaries of standard-of-care therapies (vendor-described capability)
A patient support team model combining technology and human navigation
A pharma-facing analytics dashboard for patient journey insights and recruitment barrier analysis

Where competitors may have clearer advantages

EMR-native feasibility and cohort discovery capabilities (competitors that integrate directly with health systems)
Recruitment pricing and ROI models that are more publicly described
Established navigation services with white-labeled deployments

03Field reports

What’s publicly available (constraints)

Public third-party B2B product review coverage for Leal Health’s oncology platform is limited. Searches located review pages for a separate product with a similar name that are not relevant to Leal Health’s oncology offering. Main public feedback channels for the oncology product include vendor testimonials, limited community discussion, and employee reviews focused on company operations rather than clinical outcomes. Therefore, the most relevant user sentiment available in public sources is: - Vendor-provided testimonials (marketing quotes) - Anecdotal community posts - Employee sentiment on public review sites (company operations perspective)

Selected representative observations (attributed and contextualized)

Community anecdote: A community post claimed the platform was free and characterized the vendor's generative AI features as advanced. This is anecdotal and not independently verified.
Employee feedback: Public employee reviews included both critical and positive perspectives about organizational clarity, leadership, and growth opportunities. These reflect internal operations rather than product efficacy or clinical impact.

Inferred reasons customers might choose the platform

Free patient-facing access to trial and treatment information
Patient support/navigation in addition to self-serve search
Focus on biomarker and personalized matching in vendor messaging

Potential reasons customers might avoid or discontinue use (inferred)

Because public third-party product reviews are limited, churn data are not available. Possible deterrents include:

Insufficient public documentation of security certifications and enterprise controls
Skepticism regarding vendor claims of impartial matching without transparency
Preference for EHR-integrated tools when organizations require deep health system integration

Vendor-sourced case-style claims

Vendor press releases and trade press articles describe platform launches and feature additions and include platform usage metrics. These items function as vendor or vendor-adjacent claims rather than independently validated case studies.

Critical evaluation: These announcements typically do not disclose baseline metrics, control groups, sponsor names, conversion rates across recruitment funnel stages, or detailed operational impact data.

Comparator case evidence (industry context)

For benchmarking, other vendors' documented implementations (when available) illustrate the type of evidence enterprise buyers may request, such as sponsor-validated recruitment funnel metrics, site-level operational results, screen-failure analyses, and diversity impact measurement methods. Recommendation for procurement: Request sponsor-validated recruitment funnel metrics, site-level operational results, screen-failure rates and reasons, and methodology for diversity impact measurement.

04Best fit

For patients/caregivers

Patient profile: Individuals with cancer seeking trial and treatment options, including those pursuing second opinions or biomarker-driven eligibility
Best fit situations: Patients willing to gather clinical documents (pathology, NGS reports) and coordinate follow-up conversations with oncology teams

For B2B (biopharma / CRO)

Company size: Mid-size to large sponsors running oncology programs where recruitment is a critical path
Teams/roles: Clinical operations, patient recruitment, medical affairs, trial design, diversity & inclusion, digital patient engagement
Strong fit: Sponsors seeking patient-centric messaging insights, barrier analysis, and funnel analytics in addition to matching functionality

05The pitch

What the product does (objective core value proposition)

Leal Health (formerly TrialJectory) provides an AI-supported platform focused on oncology treatment decision support and clinical-trial matching. The product operates as a centralized access point where patients, and in some cases caregivers and providers, can input diagnosis details and receive: - Matches to relevant oncology clinical trials - Information about FDA-approved standard-of-care therapies (as described in company materials and press coverage) - Patient support navigation (e.g., assistance connecting to trials, education, financial resources) Leal also offers a B2B product for pharmaceutical, biotechnology, and CRO customers that includes aggregated, de-identified analytics and patient journey insights intended to support trial design, site selection, recruitment optimization, and patient-centric program execution.

Target market and market positioning

Leal serves two primary constituencies: 1. Patients / caregivers / some providers (B2C/B2B2C): A free-to-use cancer treatment and trial matching workflow intended to help patients generate options to bring to their oncologists. 2. Biopharma, biotech, CROs (B2B): A SaaS-plus-services model (demo-driven) focused on recruitment analytics and patient insights (marketed as a patient match analytics dashboard). Market positioning themes (as expressed in vendor messaging): - Patient-centered access and navigation - Reducing sole reliance on clinicians for initial trial discovery (a positioning that may be viewed differently across provider stakeholders) - The vendor states it operates without pharmaceutical bias; this is a vendor claim that requires independent verification (see Critical Analysis)

Get a comprehensive analysis of Leal Health (fka TrialJectory) including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Sep 29, 2026

01Common complaints

If independent, peer-reviewed evidence of enrollment acceleration or reduced screen-failure rates is required prior to procurement—public evidence is limited.
If the organization requires public-facing SOC 2 Type II or ISO 27001 documentation before engaging; such certifications were not identified in public sources.
If EHR-integrated cohort discovery of structured and unstructured clinical data is the primary need—EHR-integrated solutions may be a better fit.
If transparent, published enterprise pricing is required for procurement without a demo/negotiation process.
If the compliance team requires clear documentation on regulatory status for any decision-support claims and the vendor cannot provide clarifying documentation.

Disqualifiers / poor fit

Organizations that require publicly available, auditable security certifications prior to engagement
Programs that require EHR-native cohort discovery and prescreening at scale

Publicly visible limitations

Security documentation gap: Public-facing SOC/ISO attestations and enterprise controls were not found in the reviewed materials
Evidence gap: Vendor metrics are prominent in press materials, but independent evaluations and peer-reviewed studies are limited
Limited third-party review coverage: The product lacks a robust presence on mainstream B2B review platforms specific to the oncology offering

Roadmap / future features

Vendor materials reference enhancements such as generative AI additions and expanded support capabilities; detailed roadmap timelines are not publicly available.

02Why they buy

Unique selling points reflected in vendor materials (subject to independent validation)

A single workflow that includes trial matching and summaries of standard-of-care therapies (vendor-described capability)
A patient support team model combining technology and human navigation
A pharma-facing analytics dashboard for patient journey insights and recruitment barrier analysis

Where competitors may have clearer advantages

EMR-native feasibility and cohort discovery capabilities (competitors that integrate directly with health systems)
Recruitment pricing and ROI models that are more publicly described
Established navigation services with white-labeled deployments

03Field reports

What’s publicly available (constraints)

Therefore, the most relevant user sentiment available in public sources is:

Vendor-provided testimonials (marketing quotes)
Anecdotal community posts
Employee sentiment on public review sites (company operations perspective)

Selected representative observations (attributed and contextualized)

Community anecdote: A community post claimed the platform was free and characterized the vendor's generative AI features as advanced. This is anecdotal and not independently verified.
Employee feedback: Public employee reviews included both critical and positive perspectives about organizational clarity, leadership, and growth opportunities. These reflect internal operations rather than product efficacy or clinical impact.

Inferred reasons customers might choose the platform

Free patient-facing access to trial and treatment information
Patient support/navigation in addition to self-serve search
Focus on biomarker and personalized matching in vendor messaging

Potential reasons customers might avoid or discontinue use (inferred)

Because public third-party product reviews are limited, churn data are not available. Possible deterrents include:

Insufficient public documentation of security certifications and enterprise controls
Skepticism regarding vendor claims of impartial matching without transparency
Preference for EHR-integrated tools when organizations require deep health system integration

Vendor-sourced case-style claims

Comparator case evidence (industry context)

Recommendation for procurement: Request sponsor-validated recruitment funnel metrics, site-level operational results, screen-failure rates and reasons, and methodology for diversity impact measurement.

04Best fit

For patients/caregivers

Patient profile: Individuals with cancer seeking trial and treatment options, including those pursuing second opinions or biomarker-driven eligibility
Best fit situations: Patients willing to gather clinical documents (pathology, NGS reports) and coordinate follow-up conversations with oncology teams

For B2B (biopharma / CRO)

Company size: Mid-size to large sponsors running oncology programs where recruitment is a critical path
Teams/roles: Clinical operations, patient recruitment, medical affairs, trial design, diversity & inclusion, digital patient engagement
Strong fit: Sponsors seeking patient-centric messaging insights, barrier analysis, and funnel analytics in addition to matching functionality

05The pitch

What the product does (objective core value proposition)

Matches to relevant oncology clinical trials
Information about FDA-approved standard-of-care therapies (as described in company materials and press coverage)
Patient support navigation (e.g., assistance connecting to trials, education, financial resources)

Leal also offers a B2B product for pharmaceutical, biotechnology, and CRO customers that includes aggregated, de-identified analytics and patient journey insights intended to support trial design, site selection, recruitment optimization, and patient-centric program execution.

Target market and market positioning

Leal serves two primary constituencies:

Patients / caregivers / some providers (B2C/B2B2C): A free-to-use cancer treatment and trial matching workflow intended to help patients generate options to bring to their oncologists.
Biopharma, biotech, CROs (B2B): A SaaS-plus-services model (demo-driven) focused on recruitment analytics and patient insights (marketed as a patient match analytics dashboard).

Market positioning themes (as expressed in vendor messaging):

Patient-centered access and navigation
Reducing sole reliance on clinicians for initial trial discovery (a positioning that may be viewed differently across provider stakeholders)
The vendor states it operates without pharmaceutical bias; this is a vendor claim that requires independent verification (see Critical Analysis)

Get a comprehensive analysis of Leal Health (fka TrialJectory) including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →